Antitumor vectorized oligonucleotides in a model of ewing sarcoma: Unexpected role of nanoparticles

Oligonucleotides

Volumn 19, Issue 3, 2009, Pages 255-264

  Elhamess, Hind ^a   Bertrand, Jean Rémi ^a   MacCario, Jean ^b   Maksimenko, Andrei ^a,c   Malvy, Claude ^a  

^a CNRS   (France)

^b Centre d'Etudes Pharmaceutiques   (France)

^c BioAlliance Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CHITOSAN; DEXTRAN SULFATE; HEPARIN; NANOPARTICLE; POLYCATION;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; EWING SARCOMA; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; BIOCOMPATIBLE MATERIALS; BONE NEOPLASMS; CELL PROLIFERATION; CHITOSAN; FEMALE; MICE; MICE, NUDE; NANOSPHERES; NIH 3T3 CELLS; OLIGONUCLEOTIDES, ANTISENSE; SARCOMA, EWING'S; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE;

EID: 70349294051     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2009.0197     Document Type: Article

References (64)

1. ALVAREZ-SALAS, L.M. (2008). Nucleic acids as therapeutic agents. Curr. Top Med. Chem. 8, 1379-1404.
2. ANTACHOPOULOS, C.T., GAGOS, S., ILIOPOULOS, D.C., KARAYANNACOS, P.E., TSELENI-BALAFOUTA, S., ALEVRAS, P., KOUNDOURIS, C., and SKALKEAS, G.D. (1996). Low-dose heparin treatment does not inhibit SW480 human colon cancer growth and metastasis in vivo. In Vivo. 10, 527-531.
3. BAILLY, R.A., BOSSELUT, R., ZUCMAN, J., CORMIER, F., DELATTRE, O., ROUSSEL, M., THOMAS, G., and GHYSDAEL, J. (1994). DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translo-cation in Ewing sarcoma. Mol. Cell. Biol. 14, 3230-3241.
4. BERTRAND, J.R., MAKSIMENKO, A., and MALVY, C. (2005). Short double-stranded ribonucleic acid as inhibitor of gene expression by the interference mechanism. Methods Mol. Biol. 288, 411-430.
5. BERTRAND, J.R., POTTIER, M., VEKRIS, A., OPOLON, P., MAKSIMENKO, A., and MALVY, C. (2002). Comparison of anti-sense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. 296, 1000-1004.
6. BRIGGER, I., DUBERNET, C., and COUVREUR, P. (2002). Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54, 631-651.
7. BROWN, D.A., KANG, S.H., GRYAZNOV, S.M., DEDIONISIO, L., HEIDENREICH, O., SULLIVAN, S., XU, X., and NERENBERG, M.I. (1994). Effect of phosphorothioate modif cation of oligode-oxynucleotides on specif c protein binding. J. Biol. Chem. 269, 26801-26805.
8. CHEN, X., DUDGEON, N., SHEN, L., and WANG, J.H. (2005). Chemical modif cation of gene silencing oligonucleotides for drug discovery and development. Drug Discov. Today. 10, 587-593.
9. COPPELLI, F.M., and GRANDIS, J.R. (2005). Oligonucleotides as anticancer agents: from the benchside to the clinic and beyond. Curr. Pharm. Des. 11, 2825-2840.
10. COREY, D.R. (2007). Chemical modif cation: the key to clinical application of RNA interference? J. Clin. Invest. 117, 3615-3622.
11. DELATTRE, O., ZUCMAN, J., PLOUGASTEL, B., DESMAZE, C., MELOT, T., PETER, M., KOVAR, H., JOUBERT, I., DE JONG, P., ROULEAU, G.A., AURIAS, A., and THOMAS, G. (1992). Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 359, 162-165.
12. GAO, W.Y., HAN, F.S., STORM, C., EGAN, W., and CHENG, Y. (1992). Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol. Pharmacol. 41, 223-229.
13. GEWIRTZ, A.M. (1999). Oligonucleotide therapeutics: clothing the emperor. Curr. Opin. Mol. Ther. 1, 297-306.
14. GRIMM, D., and KAY, M.A. (2007). Therapeutic application of RNAi: is mRNA targeting f nally ready for prime time?. J. Clin. Invest. 117, 3633-3641.
15. HAEUPTLE, M.T., FRANK, R., and DOBBERSTEIN, B. (1986). Translation arrest by oligodeoxynucleotides complementary to mRNA coding sequences yields polypeptides of predetermined length. Nucleic Acids Res. 14, 14 2 7-14 4 8.
16. Hu-LIESKOVAN, S., HEIDEL, J.D., BARTLETT, D.W., DAVIS, M.E., and TRICHE, T.J. (2005). Sequence-specif c knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984-8992.
17. IYER, A.K., KHALED, G., FANG, J., and MAEDA, H. (2006). Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today. 11, 812-818.
18. JÄÄSKELÄINEN, I., MÖNKKÖNEN, J., and URTTI, A. (1994). Oligonucleotide-cationic liposome interactions. A physicochem-ical study. Biochim. Biophys. Acta. 1195, 115-123.
19. KOVAR, H., ARYEE, D.N., JUG, G., HENOCKL, C., SCHEMPER, M., DELATTRE, O., THOMAS, G., and GADNER, H. (1996). EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ. 7, 429-437.
20. KOVAR, H., BAN, J., and POSPISILOVA, S. (2003). Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. Semin. Cancer Biol. 13, 275-281.
21. LAMBERT, G., BERTRAND, J.R., FATTAL, E., SUBRA, F., PINTO-ALPHANDARY, H., MALVY, C., AUCLAIR, C., and COUVREUR, P. (2000). EWS f i-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice. Biochem. Biophys. Res. Commun. 279, 401-406.
22. LEROITH, D., WERNER, H., BEITNER-JOHNSON, D., and ROBERTS, C.T., Jr. (1995). Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 16, 143-163.
23. LETSINGER, R.L. (1993). Control of properties of oligonucleotides by chemical modif cations. Nucleic Acids Symp. Ser. 29, 1-2.
24. LIU, X.J., XIE, Q., ZHU, Y.F., CHEN, C., and LING, N. (2001). Identif cation of a nonpept ide ligand t hat releases bioact ive in su-lin-like growth factor-i from its binding protein complex. J. Biol. Chem. 276, 32419-32422.
25. MAKSIMENKO, A., GOTTIKH, M.B., HELIN, V., SHABAROVA, Z.A., and MALVY, C. (1999). Physico-chemical and biological properties of antisense phosphodiester oligonucleotides with various secondary structures. Nucleosides Nucleotides. 18, 2071-2091.
26. MAKSIMENKO, A., LAMBERT, G., BERTRAND, J.R., FATTAL, E., COUVREUR, P., and MALVY, C. (2003a). Therapeutic potentialities of EWS-Fli-1 mRNA-targeted vectorized antisense oligo-nucleotides. Ann. N. Y. Acad. Sci. 1002, 72-77.
27. MAKSIMENKO, A., MALVY, C., LAMBERT, G., BERTRAND, J.R., FATTAL, E., MACCARIO, J., and COUVREUR, P. (2003b). Oligonucleotides targeted against a junction oncogene are made eff cient by nanotechnologies. Pharm. Res. 20, 1565-1567.
28. MAKSIMENKO, A., and MALVY, C. (2005a). Oncogene-targeted antisense oligonucleotides for the treatment of Ewing sarcoma. Expert Opin. Ther. Targets. 9, 825-830.
29. MAKSIMENKO, A., POLARD, V., VILLEMEUR, M., ELHAMESS, H., COUVREUR, P., BERTRAND, J.R., ABOUBAKAR, M., GOTTIKH, M., and MALVY, C. (2005b). In vivo potentialities of EWS-Fli-1 targeted antisense oligonucleotides-nanospheres complexes. Ann. N. Y. Acad. Sci. 1058, 52-61.
30. MATHES, L.E., HAYES, K.A., SWENSON, C.L., POLAS, P.J., WEISBRODE, S.E., and KOCIBA, G.J. (1991). Evaluation of antiviral activity and toxicity of dextran sulfate in feline leukemia virus-infected cats. Antimicrob. Agents Chemother. 35, 2147-2150.
31. MATSUMURA, Y., and MAEDA, H. (1986). A new concept for mac-romolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392.
32. MAY, W.A., ARVAND, A., THOMPSON, A.D., BRAUN, B.S., WRIGHT, M., and DENNY, C.T. (1997). EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat. Genet. 17, 495-497.
33. MAY, W.A., LESSNICK, S.L., BRAUN, B.S., KLEMSZ, M., LEWIS, B.C., LUNSFORD, L.B., HROMAS, R., and DENNY, C.T. (1993). The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol. Cell. Biol. 13, 7393-7398.
34. MODI, S., PRAKASH JAIN, J., DOMB, A.J., and KUMAR, N. (2006). Exploiting EPR in polymer drug conjugate delivery for tumor targeting. Curr. Pharm. Des. 12, 4785-4796.
35. MUNROE, S.H. (1988). Antisense RNA inhibits splicing of pre-mRNA in vitro. EMBO. J. 7, 2523-2532.
36. OHNO, T., RAO, V.N., and REDDY, E.S. (1993). EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res. 53, 5859-5863.
37. OUCHIDA, M., OHNO, T., FUJIMURA, Y., RAO, V.N., and REDDY, E.S. (1995). Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene. 11, 1049-1054.
38. PACINI, S., GULISANO, M., VANNUCCHI, S., and RUGGIERO, M. (2002). Poly-l-lysine/heparin stimulates angiogenesis in chick embryo chorioallantoic membrane. Biochem. Biophys. Res. Commun. 290, 820-823.
39. PEREZ, J.R., LI, Y., STEIN, C.A., MAJUMDER, S., VAN OORSCHOT, A., and NARAYANAN, R. (1994). Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oli-godeoxynucleotides. Proc. Natl. Acad. Sci. USA. 91, 5957-5961.
40. PRASEUTH, D., GUIEYSSE, A.L., ITKES, A.V., and HELENE, C. (1993). Unexpected effect of an anti-human immunodef ciency virus intermolecular triplex-forming oligonucleotide in an in vitro transcription system due to RNase H-induced cleavage of the RNA transcript. Antisense Res. Dev. 3, 33-44.
41. PRIEUR, A., TIRODE, F., COHEN, P., and DELATTRE, O. (2004). EWS/FLI-1 silencing and gene prof ling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol. Cell. Biol. 24, 7275-7283.
42. PUGLIESE, F., MENÈ, P., and CINOTTI, G.A. (1990). Glomerular polyanion and control of cell function. Am. J. Nephrol. 10, 14-18.
43. RABBITTS, T.H. (1994). Chromosomal translocations in human cancer. Nature. 372, 143-149.
44. RAO, V.N., OHNO, T., PRASAD, D.D., BHATTACHARYA, G., and REDDY, E.S. (1993). Analysis of the DNA-binding and transcrip-tional activation functions of human Fli-1 protein. Oncogene. 8, 2167-2173.
45. REDDY, E.S., and RAO, V.N. (1991). erg, an ets-related gene, codes for sequence-specif c transcriptional activators. Oncogene. 6, 2285-2289.
46. ROCKWELL, P., O'CONNOR, W.J., KING, K., GOLDSTEIN, N.I., ZHANG, L.M., and STEIN, C.A. (1997). Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucle-otides. Proc. Natl. Acad. Sci. USA. 94, 6523-6528.
47. SAWA, T., OKUMURA, Y., SUNAMOTO, J., DING, J.L., and OTTENBRITE, M. (1996). Enhanced growth of cultured f bro-blasts by a synthetic polyanionic polymer. J. Bioact. Compat. Polym. 11, 17-27.
48. SCOTLANDI, K., BENINI, S., SARTI, M., SERRA, M., LOLLINI, P.L., MAURICI, D., PICCI, P., MANARA, M.C., and BALDINI, N. (1996). Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res. 56, 4570-4574.
49. STEIN, C.A., BENIMETSKAYA, L., and MANI, S. (2005). Antisense strategies for oncogene inactivation. Semin. Oncol. 32, 563-572.
50. STEIN, C.A., and COHEN, J.S. (1988). Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res. 48, 2659-2668.
51. STEIN, C.A., and KRIEG, A.M. (1994). Problems in interpretation of data derived from in vitro and in vivo use of antisense oligode-oxynucleotides. Antisense Res. Dev. 4, 67-69.
52. TANAKA, K., IWAKUMA, T., HARIMAYA, K., SATO, H., and IWAMOTO, Y. (1997). EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J. Clin. Invest. 99, 239-247.
53. TOUB, N., BERTRAND, J.R., TAMADDON, A., ELHAMESS, H., HILLAIREAU, H., MAKSIMENKO, A., MACCARIO, J., MALVY, C., FATTAL, E., and COUVREUR, P. (2006). Eff cacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm. Res. 23, 892-900.
54. TURC-CAREL, C., PHILIP, I., BERGER, M.P., PHILIP, T., and LENOIR, G. (1983). Chromosomal translocation (11;22) in cell lines of Ewing's sarcoma. C. R. Seances Acad. Sci. III. 296, 1101-1103.
55. WALDER, R.Y., and WALDER, J.A. (1988). Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA. 85, 5011-5015.
56. WHANG-PENG, J., TRICHE, T.J., KNUTSEN, T., MISER, J., KAO-SHAN, S., TSAI, S., and ISRAEL, M.A. (1986). Cytogenetic characterization of selected small round cell tumors of childhood. Cancer Genet. Cytogenet. 21, 185-208.
57. WHITELEY, L.O., HUDSON, L. Jr., and PRETLOW, T.P. (1996). Aberrant crypt foci in the colonic mucosa of rats treated with a genotoxic and nongenotoxic colon carcinogen. Toxicol. Pathol. 24, 681-689.
58. WICKSTROM, E., BACON, T.A., and WICKSTROM, E.L. (1992). Down-regulation of c-MYC antigen expression in lymphocytes of Emu-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates. Cancer Res. 52, 6741-6745.
59. WORKMAN, J.L. (1999). Gene regulation and cancer. Gene regulation and cancer: 10th anniversary meeting of the American Association of Cancer Research Special Conferences in Cancer Research, the Homestead, Hot Springs, Virginia, USA, 14-18 October 1998. Trends Genet. 15, 9-10.
60. YASWEN, P., STAMPFER, M.R., GHOSH, K., and COHEN, J.S. (1993). Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res. Dev. 3, 67-77.
61. YEE, D., FAVONI, R.E., LEBOVIC, G.S., LOMBANA, F., POWELL, D.R., REYNOLDS, C.P., and ROSEN, N. (1990). Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential auto-crine growth factor. J. Clin. Invest. 86, 1806-1814.
62. ZHAO, Q., TEMSAMANI, J., and AGRAWAL, S. (1995). Use of cyclo-dextrin and its derivatives as carriers for oligonucleotide delivery. Antisense Res. Dev. 5, 185-192.
63. ZON, G. (1993). Oligonucleoside phosphorothioates. Methods Mol. Biol. 20, 165-189.
64. ZORIO, E., GILABERT-ESTELLES, J., ESPANA, F., RAMON, L.A., COSIN, R., and ESTELLES, A. (2008). Fibrinolysis: the key to new pathogenetic mechanisms. Curr. Med. Chem. 15, 923-929.